Cargando…
PD-1(+) mast cell enhanced by PD-1 blocking therapy associated with resistance to immunotherapy
BACKGROUND: Programmed cell death protein 1 (PD-1) antibody has been approved for a variety of tumors, but its effective rate is unsatisfactory. New evidence suggests that mast cells are an important component of the tumor microenvironment and are associated with resistance to immunotherapy, but the...
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9947072/ https://www.ncbi.nlm.nih.gov/pubmed/36018370 http://dx.doi.org/10.1007/s00262-022-03282-6 |